Research programme: siRNA therapeutics - Sirnaomics

Drug Profile

Research programme: siRNA therapeutics - Sirnaomics

Alternative Names: Acurita; FluQuit; STP302; STP523; STP601; STP702; STP801; STP805; STP900; STP902; STP909; STP911; STP916

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Sirnaomics
  • Developer Guangdong Zhongsheng Pharmaceutical; Sirnaomics
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Colorectal cancer
  • No development reported Age-related macular degeneration; Eye disorders; Glioblastoma; Human papillomavirus infections; Influenza virus infections; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Respiratory syncytial virus infections; Spinal cord injuries; Transplant rejection

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Glioblastoma in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in USA (Parenteral, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Human-papillomavirus-infections in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top